Tauriga Sciences Inc. Completes the Translations of Its 25mg Tauri-Gum Blister Pack Into the Following Languages: Mandarin Chinese, Japanese, Arabic, Hebrew, Dutch, Spanish, Polish, French, German, Italian, Finnish, and Turkish
Tauriga Sciences, Inc. (TAUG) has completed its translated packaging for Tauri-Gum™, enhancing its international expansion efforts. The new packaging supports twelve languages including Mandarin, Arabic, and Spanish, aimed at broadening its CBD and CBG infused product market. The Tauri-Gum™ line has increased the infusion concentration to 25mg. Additionally, the company is advancing its pharmaceutical development for a CBD-based product designed to assist chemotherapy patients, having filed a non-provisional patent application.
- Completion of translated packaging for Tauri-Gum™ in 12 languages, enhancing international market reach.
- Increase in product infusion concentration to 25mg, potentially improving product appeal.
- Ongoing pharmaceutical development initiative for a CBD-based product aimed at nausea regulation in chemotherapy patients.
- None.
The Company is Focused on the International Expansion of Its Flagship Brand Tauri-Gum™
NEW YORK, NY, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has completed the translated versions of its Tauri-Gum™ blister pack (packaging) into the following twelve languages: Mandarin Chinese, Japanese, Arabic, Hebrew, Dutch, Spanish, Polish, French, German, Italian, Finnish, and Turkish. The Company is focused on the international expansion of its flagship Tauri-Gum™ brand, which has recently been enhanced to 25mg infusion concentration(s) for its CBD & CBG products.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
There can be no guarantee that the Company will generate any future revenue, from bidding on U.S. Government contract(s).
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Attachment
FAQ
What is the recent development announced by Tauriga Sciences on April 1, 2021?
How many languages has Tauriga Sciences translated its Tauri-Gum™ packaging into?
What is the new infusion concentration for Tauri-Gum™ products?
What pharmaceutical initiative is Tauriga Sciences currently pursuing?
What patent application has Tauriga Sciences recently filed?
